Balanced news tone
News Sentiment
ABVC sentiment intelligence
ABVC Biopharma Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
49
Balanced news tone
50 relevant articles
Price is moving more forcefully than the current news tone suggests.
77/100 classification confidence.
directly relevant articles
high-authority source matches
-16.1% over one week, +26.9% over four weeks, trend inactive, and near fair-value range.
ABVC BioPharma (ABVC) replaces auditor and reiterates going-concern language
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
77/100 classification
One-week reaction
-16.1%
Price reacting lower
Trend fit
Trend inactive
26.9% over four weeks
Fair value
5.6%
Near fair-value range
Sentiment Mix
Positive, neutral, negative
Positive
9
Neutral
31
Negative
10
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
StockStory
Industry context
Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 15 Jul 2026 07:00
- Source
- StockStory
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
Stock Titan
Direct company coverage
ABVC BioPharma (ABVC) replaces auditor and reiterates going-concern language
ABVC BioPharma (ABVC) announced a change in its independent auditor, dismissing Simon & Edward, LLP and engaging Kreit & Chiu CPA LLP for the fiscal year ending December 31, 2026. The company noted that previous audit reports included "going-concern" language and material weaknes
- Tone
- Negative 35/100
- Event
- Market update
- Published
- 02 Jul 2026 20:02
- Source
- Stock Titan
TradingView
Direct company coverage
Price to book forward of ABVC BioPharma, Inc. – NASDAQ:ABVC
This article provides financial information for ABVC BioPharma, Inc. (NASDAQ:ABVC), specifically focusing on its price-to-book forward ratio. It highlights that the market for ABVC is currently closed with no trades. The article is hosted on TradingView, a financial platform offe
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 07:09
- Source
- TradingView
TradingView
Direct company coverage
Price to sales forward of ABVC BioPharma, Inc. – NASDAQ:ABVC
This article presents the "Price to sales forward" metric for ABVC BioPharma, Inc. (NASDAQ: ABVC). It focuses solely on this financial data point for the company, accessible through the TradingView platform. The content is essentially a data display, without further analysis or e
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 23:10
- Source
- TradingView
Intellectia AI
Direct company coverage
ABVC Should I Buy
An analysis of ABVC Biopharma Inc. (ABVC) suggests it is not a strong buy for long-term investors despite some short-term bullish momentum. Key concerns include a lack of supporting news, recent financial updates, analyst upgrades, or significant insider/hedge fund accumulation.
- Tone
- Negative 38/100
- Event
- Analyst action
- Published
- 26 Jun 2026 18:10
- Source
- Intellectia AI
TradingView
Direct company coverage
Enterprise value to EBITDA forward of ABVC BioPharma, Inc. – NASDAQ:ABVC
This article displays the enterprise value to EBITDA forward for ABVC BioPharma, Inc. (NASDAQ:ABVC) as presented on TradingView. The page shows the company's stock market information, financial data, and other related services offered by TradingView.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 11:12
- Source
- TradingView
TradingView
Direct company coverage
ABVC BioPharma, Inc. Actuals & Estimates (NASDAQ:ABVC)
This article provides an overview of ABVC BioPharma, Inc. (NASDAQ: ABVC) stock, including its current price, market capitalization, and historical performance. It also details financial estimates, such as net income for the last quarter and the upcoming earnings report date. The
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Jun 2026 18:09
- Source
- TradingView
富途牛牛
Direct company coverage
ABVC BioPharma, Inc. Announces Planned Spin-Off of BioKey (Cayman), Inc. Through Dividend Distribution of BioKey Shares to ABVC Shareholders
ABVC BioPharma (ABVC) plans to spin off its subsidiary, BioKey (Cayman), Inc., to ABVC shareholders through a dividend distribution. This strategic move aims to unlock shareholder value by separating the two distinct businesses, potentially allowing both entities to pursue indepe
- Tone
- Positive 67/100
- Event
- Capital return
- Published
- 24 Jun 2026 08:12
- Source
- 富途牛牛
dars.gov.et
Direct company coverage
ABVC BioPharma Inc. (ABVC) Q1 2025 Earnings: Net Loss of $0.06 Per Share as Stock Rises 1.53% Amid No Reported Revenue - Forward Guidance Trends
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 24 Jun 2026 07:00
- Source
- dars.gov.et
TradingKey
Direct company coverage
ABVC Biopharma Inc (ABVC) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for ABVC Biopharma Inc (ABVC), noting that no specific earnings forecast score is currently available for the company, contrasting with the Biotechnology & Medical Research industry's average score of 8.13. It also states that relevant f
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 19 Jun 2026 18:09
- Source
- TradingKey
TradingKey
Direct company coverage
ABVC Biopharma Inc (ABVC) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of ABVC Biopharma Inc (ABVC), listing major individual and corporate shareholders along with their proportions. It also presents a breakdown of shareholder types and institutional holdings over several quarters, showing changes in th
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 11:39
- Source
- TradingKey
TradingKey
Direct company coverage
ABVC Biopharma Inc (ABVC) Institutional Confidence
ABVC Biopharma Inc (ABVC) has an institutional shareholding score of 3.00, placing it 193rd out of 388 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 3.41%, indicating a quarter-over-quarter increase of 1.88%. James Simons is
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 08:39
- Source
- TradingKey
TradingKey
Direct company coverage
ABVC Biopharma Inc (ABVC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
The article discusses ABVC Biopharma Inc (ABVC) and its revenue breakdown by business segments and regional contributions. However, it explicitly states that the relevant financial data for these categories has not yet been disclosed by the company. Therefore, while the topic is
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 18 Jun 2026 06:39
- Source
- TradingKey
TradingKey
Direct company coverage
ABVC Biopharma Inc (ABVC) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of ABVC Biopharma Inc (ABVC), detailing its current price momentum score of 8.79 within the Biotechnology & Medical Research industry. It identifies key support and resistance levels for the stock, suitable for range-bound swing trading.
- Tone
- Positive 60/100
- Event
- Market update
- Published
- 18 Jun 2026 05:39
- Source
- TradingKey
TradingKey
Direct company coverage
ABVC Biopharma Inc (ABVC) Financial Health: Profitability & Balance Sheet Analysis
This article provides a financial health analysis of ABVC Biopharma Inc (ABVC) as of June 18, 2026, ranking its financial score at 8.03, which is 71 out of 389 in the Biotechnology & Medical Research industry. It highlights that the company's financial status is weak but operatin
- Tone
- Negative 33/100
- Event
- Market update
- Published
- 18 Jun 2026 03:39
- Source
- TradingKey
TradingKey
Direct company coverage
ABVC Biopharma Inc (ABVC) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of ABVC Biopharma Inc (ABVC), noting its current valuation score of 6.23, which ranks it low within the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of -3.41, which is significantly below its r
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 03:39
- Source
- TradingKey
TradingKey
Direct company coverage
ABVC Biopharma Inc (ABVC) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of ABVC Biopharma Inc.'s (ABVC) dividend history and stock split events. It indicates that the company has not distributed any dividends over the past five years and details a series of 10-for-1 merger-related stock splits that occurred on July 2
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 16 Jun 2026 07:41
- Source
- TradingKey
Finviz
Direct company coverage
ABVC - ABVC BioPharma Inc Stock Price and Quote
This article provides comprehensive stock information for ABVC BioPharma Inc., including its latest closing price, financial metrics, insider ownership, and performance indicators. It also lists recent news and press releases detailing the company's strategic initiatives, licensi
- Tone
- Positive 67/100
- Event
- Market update
- Published
- 04 Jun 2026 21:40
- Source
- Finviz
Benzinga
Direct company coverage
12 Health Care Stocks Moving In Thursday's Pre-Market Session
This article lists 12 healthcare stocks experiencing significant price movements in Thursday's pre-market session. SciSparc, BioLine Rx, Propanc Biopharma, CytoSorbents, ABVC BioPharma, and Cumberland Pharma saw gains, while ADC Therapeutics, Basel Medical Group, Picard Medical,
- Tone
- Positive 62/100
- Event
- Market update
- Published
- 04 Jun 2026 12:09
- Source
- Benzinga
Intellectia AI
Direct company coverage
ABVC PE Ratio & Valuation, Is ABVC Overvalued
ABVC Biopharma Inc. (ABVC) is currently considered undervalued, with its forward PS ratio of 0.00 significantly lower than its five-year average of -3.14. Its fair price is estimated to be between +Inf and +Inf according to a relative valuation method. The company's Price-to-Book
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Jun 2026 02:09
- Source
- Intellectia AI
DonanımHaber
Direct company coverage
ABVC BioPharma Consolidates at $1.39 as Support and Resistance Levels Narrow - Mean Reversion Trade
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 May 2026 07:00
- Source
- DonanımHaber
DonanımHaber
Direct company coverage
ABVC BioPharma Inc. (ABVC) Holds Near Support, Showing Cautious Recovery Potential - Median Line
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 25 May 2026 07:00
- Source
- DonanımHaber
DonanımHaber
Direct company coverage
ABVC BioPharma Inc. Q1 2025 Earnings: Narrowed Loss Highlights Continued Pipeline Progress - Performance Review
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 24 May 2026 07:00
- Source
- DonanımHaber
TradingView
Direct company coverage
ABVC BioPharma, Inc. 1Q 2026: Revenue ($1.55M), Net income ($1.56M), EPS ($0.06) — 10-Q Summary
ABVC BioPharma, Inc. reported a larger comprehensive and net loss in Q1 2026 compared to the prior year. The company is advancing multiple clinical programs and investing in manufacturing and CDMO capacity, but also faced an operational setback with its Vitargus® Phase II trial b
- Tone
- Negative 40/100
- Event
- Earnings
- Published
- 18 May 2026 11:10
- Source
- TradingView
Stock Titan
Direct company coverage
ABVC BioPharma (NASDAQ: ABVC) posts Q1 loss and going concern warning
ABVC BioPharma reported a Q1 2026 net loss of $1.69 million, an increase from $0.94 million a year prior, primarily due to higher operating expenses. The company's cash and cash equivalents significantly decreased to $140,324, and it reported a working capital deficit of $4.74 mi
- Tone
- Negative 18/100
- Event
- Balance sheet
- Published
- 18 May 2026 11:10
- Source
- Stock Titan
TradingView
Direct company coverage
ABVC: Q1 2026 saw a $1.69M net loss, no revenue, and a $4.74M working capital deficit
ABVC BioPharma, Inc. (ABVC) reported a net loss of $1.69 million in Q1 2026, marking a 79% increase year-over-year, with no revenue generated. The company also faced a working capital deficit of $4.74 million. Management is focusing on improving liquidity, debt reduction, and lev
- Tone
- Negative 14/100
- Event
- Balance sheet
- Published
- 18 May 2026 11:10
- Source
- TradingView
TipRanks
Direct company coverage
ABVC BioPharma Delays Quarterly SEC Filing
ABVC BioPharma announced a delay in filing its Form 10-Q (Quarter Report) for the quarter ending March 31, 2026, due to timing and workload issues, but expects to file within the SEC grace period. The company does not anticipate significant changes in operating results compared t
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 16 May 2026 01:39
- Source
- TipRanks
Stock Titan
Direct company coverage
ABVC (ABVC) files Form 12b-25: late 10-Q for March 31, 2026
ABVC BioPharma, Inc. has filed a Form 12b-25 with the SEC, indicating that it will be submitting its Form 10-Q for the period ended March 31, 2026, late. The company stated that it could not finalize the XBRL exhibit without "unreasonable effort or expense" but expects to file wi
- Tone
- Negative 38/100
- Event
- Guidance
- Published
- 15 May 2026 21:10
- Source
- Stock Titan
simplywall.st
Industry context
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st